DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.

Eva GalleBernard ThienpontSarah CappuynsTom VenkenPieter BusschaertMatthias Van HaeleEric Van CutsemTania RoskamsJos van PeltChris VerslypeJeroen DekervelDiether Lambrechts

Published in: Clinical epigenetics (2020)

We propose methylation changes underlying EMT to constitute a common resistance mechanism to cancer therapies. This process can be reversed pharmacologically and monitored non-invasively in ctDNA to predict resistance to treatment.

Keyphrases

dna methylation
papillary thyroid
epithelial mesenchymal transition
squamous cell
genome wide
gene expression
squamous cell carcinoma
lymph node metastasis
signaling pathway
young adults